EGFR and central nervous system cancer: The prognosis of gliomas is significantly affected by these molecular alterations, such as whether IDH1, IDH2, EGFR, CDKN2A, and CDKN2B are altered for adult‐type gliomas, and whether H3 K27 and H3 G34 are altered for pediatric‐type gliomas [4].